ACCESS-AD Advancing Alzheimer's Disease Care
ACCESS-AD addresses fragmented care pathways and unequal access to diagnostics by translating advanced diagnostics and monitoring approaches—such as blood-based and imaging biomarkers, digital solutions, and AI tools—into coordinated, patient-centred, equitable, and scalable care models across real-world clinical settings in Europe.
Alzheimer’s disease (AD) is a growing public health challenge in Europe’s ageing population. While Disease Modifying Therapies (DMTs) bring new therapeutic potential, fragmented care pathways, unequal diagnostic access, and healthcare limitations threaten their effectiveness and scalability. ACCESS-AD addresses this unmet need by translating advanced diagnostics and monitoring approaches—such as blood-based and imaging biomarkers, digital and AI tools—into coordinated, equitable, and scalable care across real-world clinical settings in Europe.
Aligned with IHI Call 9.2, ACCESS-AD unites and engages diverse healthcare stakeholders and integrates needs and perspectives of individuals affected by dementia to deliver inclusive, connected, and personalized care centered around the AD patient. By translating innovation into real-world practice, the project will reduce inequalities, support health policy, and improve outcomes for AD patients across Europe.
ACCESS-AD is led by
Frederik Barkhof
Professor of Neuroradiology,
Amsterdam University Medical Center (UMC)
Clinical Lead
Haitham Mohamed
Alzheimer's Program Lead
Gaby Marquardt
Head of Center for Innovation in Diagnostic
Siemens Healthineers
Industry Leads of ACCESS-AD
Niranjan Bose
Managing Director,
Health and Life Sciences, Gates Ventures
Industry co-Lead of ACCESS-AD
Dag Aarsland
Professor of Geriatric Psychiatry
King's College London
Clinical Co-Lead of ACCESS-AD
Stavanger University Hospital (SUH) will support Work Package 5 by testing real-world delivery of Diseases Modifying Therapies combined with lifestyle interventions. Our infrastructures and access to large, diverse populations are critical for inclusive care pathway validation. In addition, SUS will work on integrating primary care into diagnostic and treatment pathways to improve accessibility. Our work will contribute to develop patient-facing materials and implementation strategies.
The project aims to ensure that every individual with AD can access timely, personalized, and cost-effective care, regardless of geography or socioeconomic status. ACCESS-AD builds on local, national, and EU-level efforts to create an integrated, pan-European framework for optimized AD care
The project will:
- Establish robust coordination and governance to ensure efficient delivery and stakeholder alignment;
- Connect and expand fragmented clinical and research data through a shared platform, linking registries and initiatives across Europe;
- Reduce diagnostic access barriers by improving standardized imaging, blood-based, and digital biomarkers for clinical use;
- Develop AI-driven tools to support personalized treatment decisions;
- Generate harmonized real-world evidence on DMTs and emerging therapies;
- Assess health-economic, regulatory, and patient-reported impacts;
- Engage patients, professionals, and policymakers to ensure adoption and sustainability.
Aligned with IHI Call 9.2, ACCESS-AD unites and engages diverse healthcare stakeholders and integrates needs and perspectives of individuals affected by dementia to deliver inclusive, connected, and personalized care centered around the AD patient. By translating innovation into real-world practice, the project will reduce inequalities, support health policy, and improve outcomes for AD patients across Europe.